The Cool Down on MSN1d
Scientists issue stark warning about growing threat to public health: 'Both the disease and the underlying risk factors are evolving'Understanding the scale of the problem is the first step to addressing it. Scientists issue stark warning about growing ...
When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to ...
An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...
Lung cancer rates vary by subtype and adenocarcinoma incidence worldwide, likely due to differences in air pollution, smoking, and generational patterns.
Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...
A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...
The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback